Key Developments: Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,290.85INR
3:40am EDT
Price Change (% chg)

Rs5.45 (+0.42%)
Prev Close
Rs1,285.40
Open
Rs1,290.00
Day's High
Rs1,299.00
Day's Low
Rs1,283.00
Volume
254,735
Avg. Vol
499,223
52-wk High
Rs1,308.00
52-wk Low
Rs798.45

Search Stocks

Latest Key Developments (Source: Significant Developments)

Lupin Ltd announces allotment of equity shares
Tuesday, 26 Aug 2014 03:07am EDT 

Lupin Ltd:Allotted 134,704 fully paid up equity shares of two Indian Rupees each.  Full Article

Lupin Ltd enters into strategic distribution agreement with LG Life Sciences to launch Insulin Glargine
Wednesday, 6 Aug 2014 04:16am EDT 

Lupin Ltd:Announces strategic distribution agreement with LG Life Sciences (South Korea) to launch Insulin Glargine, a insulin analogue under brand name Basugine.According to the agreement, Lupin would be responsible for marketing and sales of Basugine in India.  Full Article

Lupin Ltd announces exercising of options
Wednesday, 25 Jun 2014 02:49am EDT 

Lupin Ltd:Has allotted 62,926 fully paid up equity shares of two Indian Rupees each.These shares have been allotted upon exercising of options granted under stock option plans of the company.  Full Article

Lupin Ltd Launches Generic Cipro for Oral Suspension in the US
Friday, 13 Jun 2014 05:55am EDT 

Lupin Ltd:Says US subsidiary, Lupin Pharmaceuticals Inc. (LPI) has launched its Ciprofloxacin for Oral Suspension, 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL) in the US having received final approval from the FDA earlier.Lupin's Ciprofloxacin Oral Suspension, 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL) is the generic equivalent of Bayer HealthCare Pharmaceuticals, Inc.'s (Bayer) Cipro Oral Suspension 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL).Says indicated for the treatment of infections caused by susceptible isolates of designated microorganisms in various conditions and patient populations.  Full Article

Venus Remedies Ltd to sell Meropenem in Australia; ties up with Lupin Ltd-Business Standard
Monday, 19 May 2014 04:04am EDT 

Venus Remedies Ltd:Said it has received marketing authorisation for its antibiotic drug Meropenem from Australian regulator TGA and has tied up with Lupin Ltd to sell the drug there-Business Standard.  Full Article

Lupin Ltd recommends final dividend
Wednesday, 7 May 2014 04:33am EDT 

Lupin Ltd:Recommends final dividend of three Indian rupees per equity share of the face value of two Indian rupees each for the year ended March 31.  Full Article

Lupin Ltd announces strategic joint venture agreement with Yoshindo Inc
Wednesday, 23 Apr 2014 01:17am EDT 

Lupin Ltd:Enters into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo) to create a new entity, YL Biologics (YLB).YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain Biosimilars including regulatory filings and obtaining marketing authorizations in Japan.New entity YLB will in-license Monoclonal Antibodies (mAbs) from Lupin and also partner with other companies across the globe for the Japanese market which already has a clear cut regulatory regime in place for the development and commercialization of Biologicals.Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical development to YLB.Enbrel is a biopharmaceutical product approved globally for treating autoimmune diseases such as Rheumatoid arthritis, Psoriasis and Ankylosing spondylitis.Enbrel is marketed in Japan by Takeda Pharmaceutical and had sales of $496 mln (IMS MAT March 2013).  Full Article

Lupin receives FDA approval for generic Actos tablets
Wednesday, 9 Apr 2014 04:44am EDT 

Lupin Ltd:receives final approval for PioglitazoneTablets USP,15mg,30mg,and 45mg from United States Food and Drugs Administration (FDA) to market generic version of Takeda Pharmaceuticals USA, Inc.’s Actos Tablets,15mg,30mg,and 45mg.Lupin Pharmaceuticals Inc. (LPI), the company’s US subsidiary would commence marketing the product.  Full Article

Lupin Ltd's subsidiary launches Generic Niaspan tablets in the US
Friday, 21 Mar 2014 04:08am EDT 

Lupin Ltd:Says its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the USFDA on March 21.  Full Article

Lupin Ltd receives FDA approval for generic Mycobutin Capsules
Wednesday, 26 Feb 2014 05:30am EST 

Lupin Ltd:Says that it has received final approval for its Rifabutin Capsules USP, 150 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Pharmacia and Upjohn company’s Mycobutin Capsules 150 mg.  Full Article

INDIA PRESS-Lupin targets 30 bln rupees India sales by year-end-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

Search Stocks